MedTrace Logo

CKD-828 S-Amlodipine Non-Responder Trial

NCT01501253 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2012-11-14

No results posted yet for this study

Summary

The aim of present study is to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg amd 2.5/80mg) compared with S-Amlodipine monotherapy (2.5mg) in hypertensive patients inadequately controlled by S-Amlodipine monotherapy.

Conditions

Interventions

DRUG

CKD-828 2.5/40mg

fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg

DRUG

CKD-828 2.5/80mg

Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg

DRUG

S-Amlodipine 2.5mg

S-Amlodipine 2.5mg monotherapy

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Ho-Joong Yoon, Ph.D · Seoul St. Mary's hospital, The catholic university of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01501253 on ClinicalTrials.gov